Cited by 304Nicotinic Acetylcholine Receptors StudyCholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatments

The DOI matches its Crossref record; 77 of the 80 references it cites were found in a registry or an index.

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease

Maelicke, Alfred, Samochocki, Marek, Jostock, Ruth, Fehrenbacher, Andreas, Ludwig, Jürgen, Albuquerque, Edson X, Zerlin, Marion·2001·Biological Psychiatry

DOI 10.1016/s0006-3223(00)01109-4

Open this paper in CoChat — free account

Abstract

Cholinesterase inhibitors are the only approved drug treatment for patients with mild to moderately severe Alzheimer's disease. Interestingly, the clinical potency of these drugs does not correlate well with their activity as cholinesterase inhibitors, nor is their action as short lived as would be expected from purely symptomatic treatment. A few cholinesterase inhibitors, including galantamine, produce beneficial effects even after drug treatment has been terminated. These effects assume modes of action other than mere esterase inhibition and are capable of inducing systemic changes. We have recently discovered a mechanism that could account, at least in part, for the above-mentioned unexpected properties of some cholinesterase inhibitors. We have found that a subgroup of cholinesterase inhibitors, including galantamine but excluding tacrine, directly interacts with nicotinic acetylcholine receptors. These compounds, named allosterically potentiating ligands, sensitize nicotinic receptors by increasing the probability of channel opening induced by acetylcholine and nicotinic agonists and by slowing down receptor desensitization. The allosterically potentiating ligand action, which is not necessarily associated with cholinesterase inhibition, has been demonstrated by whole-cell patch-clamp recordings to occur in natural murine and human neurons and in murine and human cell lines expressing various subtypes of neuronal nicotinic acetylcholine receptors.

Integrity signals

Registry

Crossref · 10.1016/s0006-3223(00)01109-4

Cites

77 of 78 references verified0 citation errors · 1 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141
A missense mutation in the neuronal nicotinic acetylcholine receptor α4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy
Steinlein, O. K., Mulley, J. C., Propping, P., Wallace, R. H., Phillips, H. A., Sutherland, G. R., Scheffer, I. E., & Berkovic, S. F. (1995) · Nature Genetics · doi:10.1038/ng1095-201 · Cited by 1,134
β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity
Wang, H.-Y., Lee, D. H. S., D’Andrea, M. R., Peterson, P. A., Shank, R. P., & Reitz, A. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5626 · Cited by 818
Handbook of Experimental Pharmacology, vol 14.
Freedman, A. D. (1972) · Archives of Internal Medicine · doi:10.1001/archinte.1972.03650020118031 · Cited by 777
Pharmacology of Nicotine: Addiction and Therapeutics
Benowitz, N. L. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.003121 · Cited by 589
Acute stress facilitates long-lasting changes in cholinergic gene expression
Kaufer, D., Friedman, A., Seidman, S., & Soreq, H. (1998) · Nature · doi:10.1038/30741 · Cited by 588
Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment
Marks, M., Pauly, Jr., Gross, S., Deneris, E., Hermans-Borgmeyer, I., Heinemann, S., & Collins, A. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-07-02765.1992 · Cited by 551
Basal forebrain neurons in the dementia of Parkinson disease
Whitehouse, P. J., Hedreen, J. C., White, C. L., & Price, D. L. (1983) · Annals of Neurology · doi:10.1002/ana.410130304 · Cited by 535

Show all 80 references

Research works printed but not linked: 5

Inestrosa NC, De Ferrari GV (2000): Acetylcholinesterase-induced β-amyloid aggregation and neurotoxicity. In: Sixth Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Abstract 87.
Lahiri DK, Farlow MR, Ge Y, Utsuki T, Greig NH (2000): Regulation of βAPP processing with cholinesterase inhibitors in neuronal cell lines. In: Sixth Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Abstract 96.
Pereira, 1994, Physostigmine and galantamine, J Pharmacol Exp Ther, 270, 768
Perry, 1999, Increased nicotinic receptors in brains from smokers, J Pharmacol Exp Ther, 289, 1545
Soreq H, Sternfeld M, Flores-Flores C, Salmon A, Ginzberg D, Seidman S (2000): Multifaced role of acetylcholinesterase in Alzheimer’s disease. In: Sixth Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Abstract 146.

Sorted by citations

Items 101–200 of 304

Stimulation of nicotinic acetylcholine receptors protects motor neurons
Nakamizo, T., Kawamata, J., Yamashita, H., Kanki, R., Kihara, T., Sawada, H., Akaike, A., & Shimohama, S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.115 · Cited by 47
Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity
Takada‐Takatori, Y., Kume, T., Sugimoto, M., Katsuki, H., Niidome, T., Sugimoto, H., Fujii, T., Okabe, S., & Akaike, A. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.08.017 · Cited by 46
Galantamine increases hippocampal insulin-like growth factor 2 expression via α7 nicotinic acetylcholine receptors in mice
Kita, Y., Ago, Y., Takano, E., Fukada, A., Takuma, K., & Matsuda, T. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2841-7 · Cited by 46
Mechanisms of Action of Cognitive Enhancers on Neuroreceptors
Narahashi, T., Moriguchi, S., Zhao, X., Marszalec, W., & Yeh, J. Z. (2004) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.27.1701 · Cited by 46
Intraspecific variability in the alkaloid metabolism of Galanthus elwesii
Berkov, S. H. (2004) · Phytochemistry · doi:10.1016/j.phytochem.2003.12.013 · Cited by 46
Galanthamine decreases genotoxicity and cell death induced by β-amyloid peptide in SH-SY5Y cell line
Ordoñez, W. O. C., Aristizábal-Pachón, A. F., Montaldi, A. P. D. L., Sakamoto‐Hojo, E. T., & Takahashi, C. S. (2016) · NeuroToxicology · doi:10.1016/j.neuro.2016.10.013 · Cited by 43
Alkaloids from Galanthus nivalis
Berkov, S. H., Codina, C. J., Viladomat, F., & Bastida, J. (2007) · Phytochemistry · doi:10.1016/j.phytochem.2007.03.025 · Cited by 45
Allosteric modulators of the α4β2 subtype of neuronal nicotinic acetylcholine receptors
Pandya, A. A., & Yakel, J. L. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.04.020 · Cited by 48
Inhibitory Potency of Choline Esterase Inhibitors on Acetylcholine Release and Choline Esterase Activity in Fresh Specimens of Human and Rat Neocortex
Jackisch, R., Förster, S., Kammerer, M. M., Rothmaier, A. K., Ehret, A., Zentner, J., & Feuerstein, T. J. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1008 · Cited by 44
Combined treatment with galanthaminium bromide, a new cholinesterase inhibitor, and RS 67333, a partial agonist of 5-HT4 receptors, enhances place and object recognition in young adult and old rats
Lamirault, L., Guillou, C., Thal, C., & Simon, H. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00351-2 · Cited by 44
Development and Application of Acute Exposure Guideline Levels (AEGLs) for Chemical Warfare Nerve and Sulfur Mustard Agents
Watson, A. P., Opresko, D. M., Young, R., & Hauschild, V. D. (2006) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/15287390500194441 · Cited by 44
Modulation of the Ca2+ conductance of nicotinic acetylcholine receptors by Lypd6
Darvas, M., Morsch, M., Rácz, I., Ahmadi, S., Swandulla, D., & Zimmer, A. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.03.007 · Cited by 46
Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation
Xie, H., Yepuri, N., Meng, Q., Dhawan, R. K., Leech, C. A., Chepurny, O. G., Holz, G. G., & Cooney, R. N. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09584-3 · Cited by 48
Early administration of galantamine from preplaque phase suppresses oxidative stress and improves cognitive behavior in APPswe/PS1dE9 mouse model of Alzheimer's disease
Saito, T., Hisahara, S., Iwahara, N., Emoto, M. C., Yokokawa, K., Suzuki, H., Manabe, T., Matsumura, A., Suzuki, S., Matsushita, T., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.09.014 · Cited by 42
Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease
Vellas, B. J., Cunha, L., Gertz, H., Deyn, P. P. D., Wesnes, K. A., Hammond, G., Schwalen, S., & on Behalf of the GAL‐INT‐28 Study Group (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x61884 · Cited by 42
Alkaloids from Hippeastrum papilio
de Andrade, J. P., Berkov, S. H., Viladomat, F., Codina, C. J., Zuanazzi, J. Â. S., & Bastida, J. (2011) · Molecules · doi:10.3390/molecules16087097 · Cited by 41
GC‐MS of amaryllidaceous galanthamine‐type alkaloids
Berkov, S. H., Viladomat, F., Codina, C. J., Suárez, S., Ravelo, Á. G., & Bastida, J. (2012) · Journal of Mass Spectrometry · doi:10.1002/jms.3059 · Cited by 40
Galantamine Population Pharmacokinetics in Patients with Alzheimer's Disease: Modeling and Simulations
Piotrovsky, V., Peer, A. V., Osselaer, N. V., Armstrong, M., & Aerssens, J. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003251853 · Cited by 40
Nicotinic receptor modulation: Advantages for successful Alzheimer’s disease therapy
Geerts, H., Finkel, L., Carr, R. A., & Spiros, Ä. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_19 · Cited by 40
Galantamine Facilitates Acquisition of Hippocampus-Dependent Trace Eyeblink Conditioning in Aged RabbitsPreprint
Weible, A. P., Oh, M. M., Lee, G., & Disterhoft, J. F. (2004) · Learning & Memory · doi:10.1101/lm.69804 · Cited by 40
Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer’s Disease Mice
Bhattacharya, S., Maelicke, A., & Montag, D. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142421 · Cited by 39
Self-citation
Progress in Clinical Neurosciences: Treatment of Alzheimer’s Disease and Other Dementias - Review and Comparison of the Cholinesterase Inhibitors
Hogan, D. B., & Patterson, C. (2002) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710000216x · Cited by 39
Alkaloids biosynthesis by Pancratium maritimum L. shoots in liquid culture
Georgiev, V., Ivanov, I. G., Berkov, S. H., & Pavlov, A. I. (2010) · Acta Physiologiae Plantarum · doi:10.1007/s11738-010-0622-7 · Cited by 38
Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer???s Disease with Cerebrovascular Disease
Small, G. W., Erkinjuntti, T., Kurz, A., & Lilienfeld, S. (2003) · CNS Drugs · doi:10.2165/00023210-200317120-00004 · Cited by 37
Treatments for Alzheimer Disease
Potyk, D. K. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000166671.86815.c1 · Cited by 37
Effects of Rivastigmine on Sustained Attention in Schizophrenia
Aasen, I., Kumari, V., & Sharma, T. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000169267.36797.76 · Cited by 37
The role of α7nAChR in controlling the anti-inflammatory/anti-arthritic action of galantamine
Gowayed, M. A., Rothe, K., Rossol, M., Attia, A. S., Wagner, U. G., Baerwald, C., El-Abhar, H. S., & Refaat, R. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113665 · Cited by 36
Future directions in the treatment of Alzheimer?s disease
Bullock, R. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.303 · Cited by 36
Treatment of Alzheimer's disease across the spectrum of severity
Shah, S., & Reichman, W. E. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.2.131 · Cited by 35
CaM kinase II and protein kinase C activations mediate enhancement of long‐term potentiation by nefiracetam in the rat hippocampal CA1 region
Moriguchi, S., Shioda, N., Han, F., Narahashi, T., & Fukunaga, K. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05440.x · Cited by 35
Current status and new developments with galantamine in the treatment of Alzheimer’s disease
Tariot, P. N. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.12.2027 · Cited by 35
Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration
Liu, X. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3145-2 · Cited by 35
The Brazilian Amaryllidaceae as a source of acetylcholinesterase inhibitory alkaloids
de Andrade, J. P., Giordani, R. B., Torras‐Claveria, L., Pigni, N. B., Berkov, S. H., Font‐Bardía, M., Calvet, T., Konrath, E. L., Bueno, K. S. D. S., Sachett, L. G., et al. (2015) · Phytochemistry Reviews · doi:10.1007/s11101-015-9411-7 · Cited by 34
Amaryllidaceae Alkaloids of Different Structural Types from Narcissus L. cv. Professor Einstein and Their Cytotoxic Activity
Breiterova, K. H., Koutová, D., Maříková, J., Havelek, R., Kuneš, J., Majorošová, M., Opletal, L., Hošťálková, A., Jenčo, J., Řezáčová, M., et al. (2020) · Plants · doi:10.3390/plants9020137 · Cited by 34
Cholinesterase as a Target for Drug Development in Alzheimer’s Disease
Sharma, P. A., Tripathi, M. K., & Shrivastava, S. K. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0163-1_18 · Cited by 33
N-oxide alkaloids from Crinum amabile (Amaryllidaceae)
Tallini, L. R., Torras‐Claveria, L., Borges, W. D. S., Kaiser, M., Viladomat, F., Zuanazzi, J. Â. S., & Bastida, J. (2018) · Molecules · doi:10.3390/molecules23061277 · Cited by 32
Unraveling the medicinal potential and conservation of Indian Crinum (Amaryllidaceae) species
Chahal, S., Lekhak, M. M., Kaur, H., Shekhawat, M. S., Dey, A., Jha, P., Pandey, D. K., & Kumar, V. (2020) · South African Journal of Botany · doi:10.1016/j.sajb.2020.04.029 · Cited by 32
α7 Nicotinic acetylcholine receptor gene and reduced risk of Alzheimer’s disease
Carson, R., Craig, D., McGuinness, B., Johnston, J. A., O’Neill, F. A., Passmore, A. P., & Ritchie, C. W. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2007.052704 · Cited by 31
Steady‐State Pharmacokinetics of Galantamine Are Not Affected by Addition of Memantine in Healthy Subjects
Yao, C., Raoufinia, A., Gold, M., Nye, J. S., Ramael, S., Padmanabhan, M., Walschap, Y., Verhaeghe, T., & Zhao, Q. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005274551 · Cited by 32
Hippeastrum reticulatum (Amaryllidaceae): Alkaloid Profiling, Biological Activities and Molecular Docking
Tallini, L. R., Osorio, E. H., Santos, V., Borges, W. D. S., Kaiser, M., Viladomat, F., Zuanazzi, J. Â. S., & Bastida, J. (2017) · Molecules · doi:10.3390/molecules22122191 · Cited by 31
Optimal Dosing of Galantamine in Patients with Mild or Moderate Alzheimerʼs Disease
Aronson, S. M., van Baelen, B., Kavanagh, S., & Schwalen, S. (2009) · Drugs & Aging · doi:10.2165/00002512-200926030-00004 · Cited by 31
Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes
Froestl, W., Muhs, A., & Pfeifer, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121537 · Cited by 31
Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model
Yanagida, T., Takeuchi, H., Kitamura, Y., Takata, K., Minamino, H., Shibaike, T., Tsushima, J., Kishimoto, K., Yasui, H., Taniguchi, T., et al. (2008) · Neuroscience Research · doi:10.1016/j.neures.2008.09.003 · Cited by 31
Mecamylamine interactions with galantamine and donepezil: effects on learning, acetylcholinesterase, and nicotinic acetylcholine receptors
Woodruff‐Pak, D. S., Vogel, R. W., & Wenk, G. L. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00872-2 · Cited by 31
Galantamine enhancement of long‐term potentiation is mediated by calcium/calmodulin‐dependent protein kinase II and protein kinase C activation
Moriguchi, S., Shioda, N., Han, F., Yeh, J. Z., Narahashi, T., & Fukunaga, K. (2009) · Hippocampus · doi:10.1002/hipo.20572 · Cited by 31
Potentiation of N-Methyl-d-aspartate-Induced Currents by the Nootropic Drug Nefiracetam in Rat Cortical Neurons
Moriguchi, S., Marszalec, W., Zhao, X., Yeh, J. Z., & Narahashi, T. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.050823 · Cited by 31
Effects of galantamine on β-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells
Li, Q., Wu, D., Zhang, L., & Zhang, Y. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.06.008 · Cited by 30
In vivo and in vitro study of the influence of the anticholinesterase drug galantamine on motor and evacuative functions of rat gastrointestinal tract
Turiiski, V. I., Krustev, A. D., Sirakov, V. N., & Getova, D. P. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.054 · Cited by 30
Modulation of cholinergic transmission enhances excitability of hippocampal pyramidal neurons and ameliorates learning impairments in aging animals
Disterhoft, J. F. (2003) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2003.08.004 · Cited by 30
Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer’s disease in Wistar rats
Rajkumar, M., Sakthivel, M., Senthilkumar, K., Thangaraj, R., & Kannan, S. (2022) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100100 · Cited by 29
Roles of Nicotinic Acetylcholine Receptors in the Pathology and Treatment of Alzheimer’s and Parkinson’s Diseases
Shimohama, S., & Kawamata, J. (2018) · Springer eBooks · doi:10.1007/978-981-10-8488-1_8 · Cited by 33
GALANTAMINE PROVIDES BROAD BENEFITS IN PATIENTS WITH ‘ADVANCED MODERATE’ ALZHEIMER'S DISEASE (MMSE ≤12) FOR UP TO SIX MONTHS
Wilkinson, D., Hock, C., Farlow, M. R., van Baelen, B., & Schwalen, S. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11310.x · Cited by 29
Gonadoprotective ability ofVincetoxicum arnottianumextract against bisphenol A‐induced testicular toxicity and hormonal imbalance in male Sprague Dawley rats
Zahra, Z., Khan, M. R., Majid, M., Maryam, S., & Sajid, M. (2020) · Andrologia · doi:10.1111/and.13590 · Cited by 28
Effects of Galantamine, a Nicotinic Allosteric Potentiating Ligand, on Nicotine-Induced Catecholamine Release in Hippocampus and Nucleus Accumbens of Rats
Sharp, B. M., Yatsula, M. S., & Fu, Y. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.063586 · Cited by 28
Advances in the In vitro and In vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators
Wilkerson, J. L., Deba, F., Crowley, M. L., Hamouda, A. K., & McMahon, L. R. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108008 · Cited by 29
Alkaloid profile and cholinesterase inhibition activity of five species of Amaryllidaceae family collected from Mérida state-Venezuela
Rojas-Vera, J. D. C., Buitrago, A., Possamai, L. M., Timmers, L. F. S. M., Tallini, L. R., & Bastida, J. (2020) · South African Journal of Botany · doi:10.1016/j.sajb.2020.03.001 · Cited by 27
Changes in apolar metabolites during in vitro organogenesis of Pancratium maritimum
Berkov, S. H., Pavlov, A. I., Georgiev, V., Weber, J., Bley, T., Viladomat, F., Bastida, J., & Codina, C. J. (2010) · Plant Physiology and Biochemistry · doi:10.1016/j.plaphy.2010.07.002 · Cited by 27
Quantitative Determination of Galantamine in Human Plasma by Sensitive Liquid Chromatography--Tandem Mass Spectrometry Using Loratadine as an Internal Standard
Nirogi, R. V. S., Kandikere, V. N., Mudigonda, K., & Maurya, S. (2007) · Journal of Chromatographic Science · doi:10.1093/chromsci/45.2.97 · Cited by 27
Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation
Mohamed, T. S., Jayakar, S. S., & Hamouda, A. K. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00071 · Cited by 27
Galantamine improves apomorphine‐induced deficits in prepulse inhibition via muscarinic ACh receptors in mice
Yano, K., Koda, K., Ago, Y., Kobayashi, H., Kawasaki, T., Takuma, K., & Matsuda, T. (2008) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00037.x · Cited by 27
Galantamine increases excitability of CA1 hippocampal pyramidal neurons
Oh, M. M., Wu, W., Power, J., & Disterhoft, J. F. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.08.063 · Cited by 27
Modulation of N-Methyl-d-aspartate Receptors by Donepezil in Rat Cortical Neurons
Moriguchi, S., Zhao, X., Marszalec, W., Yeh, J. Z., & Narahashi, T. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087908 · Cited by 27
Effect of Dietary Iron Loading on Recognition Memory in Growing Rats
Han, M., & Kim, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120609 · Cited by 26
Pharmacokinetic and Safety Assessments of Galantamine and Risperidone after the Two Drugs Are Administered Alone and Together
Huang, F., Lasseter, K. C., Janssens, L., Verhaeghe, T., Lau, H., & Zhao, Q. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/0091270002042012005 · Cited by 26
Pharmacologic Treatment Expectations in the Management of Dementia with Lewy Bodies
Kaufer, D. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000074680 · Cited by 26
Galantamine attenuates the heroin seeking behaviors induced by cues after prolonged withdrawal in rats
Liu, H., Lai, M., Zhou, X., Zhu, H., Liu, Y., Sun, A., Ma, B., Zhang, F., & Zhou, W. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.031 · Cited by 25
Galantamine prevents and reverses neuroimmune induction and loss of adult hippocampal neurogenesis following adolescent alcohol exposure
Macht, V. A., Vetreno, R. P., Elchert, N., & Crews, F. T. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02243-7 · Cited by 24
Nicotinic component of galantamine in the regulation of amyloid precursor protein processing
Lenzken, S. C., Lanni, C., Govoni, S. M., Lucchelli, A., Schettini, G., & Racchi, M. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.11.008 · Cited by 24
Cholinesterase Inhibitors as Chemical Warfare Agents
Watson, A. P., Bakshi, K. S., Opresko, D. M., Young, R., Hauschild, V. D., & King, J. F. (2006) · Elsevier eBooks · doi:10.1016/b978-012088523-7/50006-5 · Cited by 24
In-vitro evaluation of the P-glycoprotein interactions of a series of potentially CNS-active Amaryllidaceae alkaloids
Eriksson, A. H., Rønsted, N., Güler, S., Jäger, A. K., Sendra, J. R., & Brodin, B. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01536.x · Cited by 23
Elicitation of galanthamine production by leucojum aestivum shoots grown in temporary immersion system
Schumann, A., Torras‐Claveria, L., Berkov, S. H., Claus, D., Gerth, A., Bastida, J., & Codina, C. J. (2012) · Biotechnology Progress · doi:10.1002/btpr.1677 · Cited by 23
(−)-9-Dehydrogalanthaminium bromide, a new cholinesterase inhibitor, enhances place and object recognition memory in young and old rats
Lamirault, L., Guillou, C., Thal, C., & Simon, H. (2003) · Neurobiology of Learning and Memory · doi:10.1016/s1074-7427(03)00064-9 · Cited by 23
Quantitative determination of Amaryllidaceae alkaloids fromGalanthus reginae-olgaesubsp.vernalisandin vitroactivities relevant for neurodegenerative diseases
Conforti, F., Loizzo, M. R., Marrelli, M., Menichini, F., Statti, G. A., Uzunov, D., & Menichini, F. (2009) · Pharmaceutical Biology · doi:10.3109/13880200903029308 · Cited by 22
Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease
Monsch, A. U., & Giannakopoulos, P. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003890 · Cited by 22
Effects of donepezil treatment on rat nicotinic acetylcholine receptor levels in vivo and in vitro
Reid, R. T., & Sabbagh, M. N. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2003-5602 · Cited by 22
The persistent impact of adolescent binge alcohol on adult brain structural, cellular, and behavioral pathology: A role for the neuroimmune system and epigenetics
Coleman, L. G., Crews, F. T., & Vetreno, R. P. (2021) · International review of neurobiology · doi:10.1016/bs.irn.2021.08.001 · Cited by 26
Activation of α7 Nicotinic Acetylcholine Receptor Ameliorates Zymosan-Induced Acute Kidney Injury in BALB/c Mice
Ibrahim, S. M., Al‐Shorbagy, M. Y., Abdallah, D. M., & El-Abhar, H. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-35254-1 · Cited by 21
Neuronal Nicotinic Acetylcholine Receptor Modulators: Recent Advances and Therapeutic Potential
Breining, S. R., Mazurov, A. A., & Miller, C. H. (2005) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(05)40001-9 · Cited by 21
Effects of galantamine in patients with mild Alzheimer's disease
Jm, O., Gw, S., Hammond, G., van Baelen, B., & Schwalen, S. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x12555 · Cited by 21
Biological flora of Central Europe: Leucojum aestivum L.
Parolo, G., Abeli, T., Rossi, G., Dowgiallo, G., & Matthies, D. (2011) · Perspectives in Plant Ecology Evolution and Systematics · doi:10.1016/j.ppees.2011.05.004 · Cited by 21
Present and prospective clinical therapeutic regimens for Alzheimer’s disease
Husain, M. M. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2012 · Cited by 21
Galantamine: use in Alzheimer’s disease and related disorders
Bullock, R. A. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.2.153 · Cited by 21
Enhancement of nicotinic receptors alleviates cytotoxicity in neurological disease models
Kawamata, J., Suzuki, S., & Shimohama, S. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310397691 · Cited by 17
Allosterism of Nicotinic Acetylcholine Receptors: Therapeutic Potential for Neuroinflammation Underlying Brain Trauma and Degenerative Disorders
Mitra, S., Khatri, S. N., Maulik, M., Bult-Ito, A., & Schulte, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144918 · Cited by 21
Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent
Deutsch, S. I., Rosse, R. B., Billingslea, E. N., Bellack, A. S., & Mastropaolo, J. P. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00642-8 · Cited by 20
Potential applications of nicotinic ligands in the laboratory and clinic
Dani, J. A., Biasi, M. D., Liang, Y., Peterson, J., Zhang, L., Zhang, T., & Zhou, F.-M. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.07.036 · Cited by 20
Protective role of phenylethanoid glycosides, Torenoside�B and Savatiside A, in Alzheimer's disease
Ji, S., Li, S., Zhao, X., Kang, N., Cao, K.-K., Zhu, Y., Peng, P., Fan, J., Xu, Q., Yang, S., et al. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7355 · Cited by 19
Cytotoxic activities of selected plants of the family Amaryllidaceae on brain tumour cell lines
Omoruyi, S. I., Kangwa, T. S., Ibrakaw, A. S., Cupido, C. N., Marnewick, J. L., Ekpo, O. E., & Hussein, A. A. (2020) · South African Journal of Botany · doi:10.1016/j.sajb.2020.09.015 · Cited by 19
Effects of galantamine on l-NAME-induced behavioral impairment in Y-maze task in mice
Tanaka, K.-I., Yagi, T., Shimakoshi, R., Azuma, K., Nanba, T., Ogo, H., Tamura, A., & Asanuma, M. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.07.024 · Cited by 19
Cholinergic Modulation by Opioid Receptor Ligands: Potential Application to Alzheimer's Disease
Motel, W. C., Coop, A., & Cunningham, C. W. (2013) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955713804999784 · Cited by 19
Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen
Thavichachart, N., Phanthumchinda, K., Chankrachang, S., Praditsuwan, R., Nidhinandana, S., Senanarong, V., & Poungvarin, N. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00892.x · Cited by 19
Natural Compounds and Their Derivatives as Multifunctional Agents for the Treatment of Alzheimer Disease
Tundis, R., Loizzo, M. R., Nabavi, S. M., Orhan, İ. E., Skalicka‐Woźniak, K., D’Onofrio, G., & Aiello, F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809593-5.00003-3 · Cited by 19
Simultaneous determination of galanthamine and lycorine in Lycoris radiata by a capillary electrophoresis with an electrochemiluminescence method
Wang, Y., Zhu, G., Li, X., & Hao, Z. (2014) · Journal of Separation Science · doi:10.1002/jssc.201400639 · Cited by 18
α4 nicotinic acetylcholine receptor modulated by galantamine on nigrostriatal terminals regulates dopamine receptor-mediated rotational behavior
Inden, M., Takata, K., Yanagisawa, D., Ashihara, E., Tooyama, I., Shimohama, S., & Kitamura, Y. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.02.008 · Cited by 18
NAChR α4β2 Subtype and their Relation with Nicotine Addiction, Cognition, Depression and Hyperactivity Disorder
Laikowski, M. M., Reisdorfer, F., & Moura, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180410105135 · Cited by 17
Chemical Profiling and Cholinesterase Inhibitory Activity of Five Phaedranassa Herb. (Amaryllidaceae) Species from Ecuador
Moreno, R., Tallini, L. R., Cristina, S., Osorio, E. H., Montero, E., Bastida, J., Oleas, N. H., & León, K. A. (2020) · Molecules · doi:10.3390/molecules25092092 · Cited by 17
The Influence of Galantamine on Reaction Time, Attention Processes, and Performance Variability in Elderly Alzheimer Patients
Gorus, E., Lambert, M., Raedt, R. D., & Mets, T. F. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318032eadb · Cited by 17
Pharmacological Study on Alzheimer’s Drugs Targeting Calcium/Calmodulin-Dependent Protein Kinase II
Moriguchi, S. (2011) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11r06cp · Cited by 16
Structural Features and Hydrogen‐Bond Properties of Galanthamine and Codeine: An Experimental and Theoretical Study
Atkinson, A. P., Baguet, É., Galland, N., Questel, J. L., Planchat, A., & Graton, J. (2011) · Chemistry - A European Journal · doi:10.1002/chem.201100475 · Cited by 16
Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models
Smith, L. C., & George, O. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108225 · Cited by 18

Authors: Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X., & Zerlin, M.
Affiliations: Johannes Gutenberg University Mainz (DE)
Corresponding author: Maelicke, Alfred
ORCID: Jostock, Ruth
Venue: Biological Psychiatry
Publisher: Elsevier BV
Published: 2001-02
Volume: 49
Issue: 3
Pages: 279-288
ISSN: 0006-3223 (ISSN-L)
DOI: 10.1016/s0006-3223(00)01109-4
OpenAlex: W2043467860
Cited by: 303
References: 80
Citations by year: 2026: 7 · 2025: 3 · 2024: 4 · 2023: 1 · 2022: 6 · 2021: 9 · 2020: 17 · 2019: 10 · 2018: 13 · 2017: 6 · 2016: 11 · 2015: 11 · 2014: 6 · 2013: 11 · 2012: 9
FWCI: 1.65
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Biological Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: galantamine, nicotinic acetylcholine receptors, Alzheimer's disease, cholinesterase inhibitors, tacrine, receptor desensitization, acetylcholine, off-target effects
MeSH terms: Allosteric Regulation, Allosteric Site, Alzheimer Disease, Animals, Cell Line, Cholinesterase Inhibitors, Galantamine, Humans, Neurons, Receptors, Nicotinic, Patch-Clamp Techniques, Nootropic Agents, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks